Nanobiotix Sa ADR (NBTX)
NASDAQ:NBTX
Want to see NBTX full AI Analyst Report?
NBTX Stock Chart & Stats
$33.79
-$0.03(-1.02%)
At close: 4:00 PM EST
$33.79
-$0.03(-1.02%)
Day’s Range― - ―
52-Week Range$4.50 - $57.14
Previous CloseN/A
Volume23.08K
Average Volume (3M)74.66K
Market Cap
$1.79B
Enterprise Value$1.60B
Total Cash (Recent Filing)$52.75M
Total Debt (Recent Filing)$95.32M
Price to Earnings (P/E)―
Beta0.95
Next Earnings
Sep 30, 2026EPS Estimate
-0.29Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.50
Shares Outstanding50,619,583
10 Day Avg. Volume73,830
30 Day Avg. Volume74,659
Financial Highlights & Ratios
PEG Ratio0.60
Price to Book (P/B)-11.14
Price to Sales (P/S)31.74
P/FCF Ratio-27.70
Enterprise Value/Market Cap0.89
Enterprise Value/Revenue54.00
Enterprise Value/Gross Profit54.00
Enterprise Value/Ebitda-132.64
Forecast
1Y Price Target
$34.33Price Target Upside1.61% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.23
Revenue Forecast (FY)$40.51M
Bulls Say, Bears Say
Bulls Say
Extended Cash RunwayA substantial May 2026 equity raise and existing cash extend the company’s operating runway into 2029. That durable financing reduces near-term refinancing risk, lets management execute late-stage trials and platform work, and provides time to reach registration milestones or secure non-dilutive deals.
Clinical Traction & Regulatory AccelerationEarly high response rates in JNJ‑sponsored CONVERGE and an FDA-accepted protocol amendment to fast-track NANORAY-312 materially strengthen the clinical and regulatory path. These durable developments can accelerate potential approvals, increase partner milestone probability, and de-risk commercialization timing over the medium term.
Proprietary IP & Platform DiversificationA broad patent estate and multiple platform programs (nanoradioenhancers, Nanoprimer delivery tech) create structural competitive barriers and multiple commercialization routes. Platform diversity supports partnering, royalty streams and cross-indication scalability, reducing single-product binary risk over time.
Bears Say
Balance Sheet PressurePersistent negative equity and elevated debt relative to assets constrain financial flexibility and increase refinancing or covenant risk. Structurally, this limits the company’s ability to absorb clinical setbacks, negotiate favorable partner terms, or pursue M&A without further dilution or expensive financing.
Persistent Cash BurnConsistent negative operating and free cash flow indicate reliance on external funding to sustain operations. Even with an extended runway, ongoing cash burn creates structural dilution risk and forces management to prioritize financing and milestones rather than organic scaling or broader R&D diversification.
Volatile Revenue & No ProfitabilityRevenue is uneven and driven by collaborations rather than product sales, and the company remains unprofitable. This structural reliance on milestone/licensing income rather than sustainable commercial revenues leaves long-term cash flows uncertain until approvals, limiting predictable earnings conversion and heightening execution risk.
NBTX FAQ
What was Nanobiotix Sa ADR’s price range in the past 12 months?
Nanobiotix Sa ADR lowest stock price was $4.50 and its highest was $57.14 in the past 12 months.
What is Nanobiotix Sa ADR’s market cap?
Nanobiotix Sa ADR’s market cap is $1.79B.
When is Nanobiotix Sa ADR’s upcoming earnings report date?
Nanobiotix Sa ADR’s upcoming earnings report date is Sep 30, 2026 which is in 97 days.
How were Nanobiotix Sa ADR’s earnings last quarter?
Currently, no data Available
Is Nanobiotix Sa ADR overvalued?
According to Wall Street analysts Nanobiotix Sa ADR’s price is currently Undervalued.
Does Nanobiotix Sa ADR pay dividends?
Nanobiotix Sa ADR does not currently pay dividends.
What is Nanobiotix Sa ADR’s EPS estimate?
Nanobiotix Sa ADR’s EPS estimate is -0.29.
How many shares outstanding does Nanobiotix Sa ADR have?
Nanobiotix Sa ADR has 50,619,583 shares outstanding.
What happened to Nanobiotix Sa ADR’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Nanobiotix Sa ADR?
Currently, no hedge funds are holding shares in NBTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Nanobiotix Stock Smart Score
Company Description
Nanobiotix Sa ADR
Nanobiotix S.A. is a clinical-stage biotechnology firm focused on developing innovative therapeutic solutions for cancer. The company's leading experimental drug, NBTXR3, is a sterile aqueous suspension comprising crystalline hafnium oxide nanoparticles. This treatment is currently undergoing development for its potential application in a broad spectrum of cancers, including soft tissue sarcoma, various head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has established a strategic collaboration with LianBio for the development and commercialization of NBTXR3 within key Asian markets, specifically Greater China, South Korea, Singapore, and Thailand. Founded in 2003, the company's main operations are situated in Paris, France.
NBTX Company Deck
NBTX Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
Positive overall. The company reported meaningful financial and operational improvements driven by (a) removal of large development obligations via the Janssen amendment, (b) nondilutive royalty financing that materially strengthens near-term liquidity, and (c) clinical progress across multiple programs including encouraging early CONVERGE lead-in data and continued Curadigm platform advancement (patents, MTAs, CMC/GMP start). Key risks remain: the FY2025 revenue uplift is largely a one‑time accounting effect, clinical readouts (notably CONVERGE and the Phase III head & neck study) are controlled by J&J and many pivotal data points are not expected until 2027, and the stated runway depends on receipt of remaining financing and potential milestone receipts. On balance, the positives (stronger cash runway, lower burn, decreased net loss, strategic financing, multiple clinical catalysts and platform progress) outweigh the listed risks and uncertainties.View all NBTX earnings summariesNBTX Stock 12 Month Forecast
Average Price Target
$34.33
▲(1.61% Upside)
Technical Analysis
―
Bicara Therapeutics Inc.
―
Zenas BioPharma, Inc.
―
Upstream Bio, Inc.
―
Septerna, Inc.
―
Ownership Overview
―
Insiders
<0.01% Mutual Funds
11.11% Other Institutional Investors
88.88% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---